Verona in pact with Nuance Pharma

Country

United Kingdom

Verona Pharma Plc has agreed to grant exclusive rights to Nuance Pharma Ltd of Shanghai, China for its respiratory treatment ensifentrine in exchange for an upfront payment of $25 million in cash and other considerations. The rights relate to the development and commercialisation of ensifentrine in mainland China and adjacent territories. Ensifentrine is an investigational therapy, currently in a global Phase 3 programme for the treatment of chronic obstructive pulmonary disease (COPD). Late-stage clinical trials are currently underway at sites in the US, Europe and South Korea.